Neuromedin S (NMS), a 36 amino acid peptide structurally related to neuromedin U, identified in rat brain as ligand for the G protein-coupled receptor FM4/TGR-1, also termed neuromedin U receptor type-2 (NMU2R). Its central expression is restricted to the suprachiasmatic nucleus, and involved in the regulation of dark light rhythms and suppression of food intake. Stimulatory role of NMS on hypo...

G J. Chandran and associates, in their report of a case of neuroleptic malignant syndrome (NMS), describe an 81-year-old man who was given 2 dopamine D2 blocking agents, with a total daily dose roughly equivalent to 9 mg of haloperidol, a very high dosage for someone this age. Within 3 days, one of these drugs was stopped, but the dosage of the other was increased. Although we do not know exact...

neuroleptic malignant syndrome (nms) is a rare but life-threatening idiosyncratic side effect resulting from neuroleptic drugs. nms mainly occurs in patients treated with high-potency typical antipsychotics, but rarely caused by atypical antipsychotics. although nms is less common with atypical antipsychotic, but it seems that its incidence is rising due to increased administration of such drug...

During the past decade the view of Parkinson's disease (PD) as a motor disorder has changed significantly and currently it is recognized as a multisystem process with diverse non-motor signs (NMS). In addition to been extremely common, these NMS play a major role in undermining functionality and quality of life. On the other hand, NMS are under recognized by physicians and neglected by patients...

Nanotechnology has created opportunities for engineers to manufacture superior and more efficient devices and products. Nanomaterials (NMs) are now widely used in consumer products as well as for research applications. However, while the lists of known toxic effects of nanomaterials and nanoparticles (NPs) continue to grow, there is still a vast gap in our knowledge about the genotoxicity of NM...

Neuroleptic malignant syndrome (NMS) is a potentially life-threatening idiosyncratic reaction generally associated with neuroleptics. NMS is characterized by hyperthermia, extrapyramidal symptoms, elevated creatinine kinase (CK), altered mental state, leukocytosis, and problems with vegetative functions. Due to its lower affinity for dopaminergic receptors and higher affinity for serotonin rece...

The neuroleptic malignant syndrome (NMS) commonly occurs on treatment with neuroleptics, it is also reported in patients who suddenly stop drugs like levodopa, amitriptyline and imipramine. We report a case of NMS, which occurred in a patient on lithium, haloperidol and trihexyphenidyl (THP) after sudden discontinuation of THP. The cholinergic system, through its effect on the dopaminergic syst...

Neuroleptic malignant syndrome (NMS) is a rare, life-threatening but potentially treatable condition. This study was performed to investigate the clinical spectrum, antecedent events and outcome of NMS patients admitted in the Neurology department of a large teaching hospital of North India. Fourteen cases of NMS were taken after a thorough search during a three-year period (May 2000 to April 2...

We compared two commercial assays for measurement of serum thyroglobulin [Nuclear Medical Systems (NMS) and "CIS" (Damon Diagnostics)] with each other and with one developed at Stanford (J Clin Endocrinol Metab 49:557-564, 1979). The NMS assay is a competitive-binding RIA, the CIS and Stanford assays are two-site immunoradiometric assays. The kit standards varied in thyroglobulin concentration....

Introduction: A rare and atypical form of Neuroleptic Malignant Syndrome (NMS) can be a deceptive and life threatening condition if not diagnosed properly in acute and critical care settings. Methods: The management of a patient presenting with atypical NMS without prominent rigidity, but with extensive rhabdomyolysis after the administration of haloperidol and ziprasidone is described in this ...